Biological therapies for the treatment of psoriasis in pediatrics

References

• Griffiths CEM, Armstrong AW, Gudjonsson J, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315.
   PubMed Web of Science ®Google Scholar
• Campanati A, Marani A, Martina E, et al. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9(11):1511.
   PubMed Web of Science ®Google Scholar
• Bronckers IMGJ, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Pediatr Drugs. 2015;17:373–384. doi: 10.1007/s40272-015-0137-1
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–1541.
   PubMedGoogle Scholar
• De Jager MEA, van de Kerkhof PCM, De Jong EMGJ, et al. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals. J DermatolTreat. 2009;20:254–258. doi: 10.1080/09546630902911847
   Google Scholar
• Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–636.
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40.
   PubMed Web of Science ®Google Scholar
• Eisert L, Augustin M, Et at BS. S2k guidelines for the treatment of psoriasis in children and adolescents – short version part 1. J Dtsch Dermatol Ges. 2019;17:856–870. doi: 10.1111/ddg.13907
   Google Scholar
• Peris K, Belloni Fortina A, Bianchi L, et al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatol Ther. 2022;12(8):1753–1775. doi: 10.1007/s13555-022-00758-2
   PubMed Web of Science ®Google Scholar
• Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147–1157.
   PubMed Web of Science ®Google Scholar
• Hebert AA, Browning J, Kwong PC, et al. Managing pediatric psoriasis: update on treatments and challenges—A review. J Dermatol Treat. 2022;33(5):2433–2442.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Balato A, et al. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther. 2016;6(2):125–142.
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Balato A, et al. Psoriasis in children: a review. Curr Pediatr Rev. 2015;11:10–26. doi: 10.2174/1573400511666150504125456
   PubMedGoogle Scholar
• Ji YZ, Liu SR. Koebner phenomenon leading to the formation of new psoriatic lesions: evidences and mechanisms. Biosci Rep. 2019;39(12):BSR20193266. doi: 10.1042/BSR20193266
   PubMed Web of Science ®Google Scholar
• Ozden MG, Tekin NS, Gürer MA, et al. Environmental risk factors in pediatric psoriasis: a multicenter case-control study. Pediatr Dermatol. 2011;28:306–312. doi: 10.1111/j.1525-1470.2011.01408.x
   PubMed Web of Science ®Google Scholar
• Cordoro KM, Hitraya-Low M, Taravati K, et al. Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol. 2017;77:417–424. doi: 10.1016/j.jaad.2017.05.017
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Y, Yang X, et al. Characterization of Th17 and FoxP3+Treg cells in paediatric psoriasis patients. Scand J Immunol. 2016;83(3):174–180.
   PubMed Web of Science ®Google Scholar
• Kim JC, Kim SM, Soh BW, et al. Comparison of cytokine expression in paediatric and adult psoriatic skin. Acta Derm Venereol. 2020;100:1–2. doi: 10.2340/00015555-3396
   Web of Science ®Google Scholar
• Kim HO, Kang SY, Kim JC, et al. Pediatric psoriasis: from New insights into pathogenesis to updates on treatment. Biomedicines. 2021;9(8):940.
   PubMed Web of Science ®Google Scholar
• Belloni Fortina A, Bardazzi F, Berti S, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017;176(10):1339–1354.
   PubMed Web of Science ®Google Scholar
• Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161–201. doi: 10.1016/j.jaad.2019.08.049
   PubMed Web of Science ®Google Scholar
• Bruins FM, Van Acht MR, Bronckers IMG, et al. Real-world methotrexate use in a prospective cohort of paediatric patients with plaque psoriasis: effectiveness, adverse events and folic acid regimen. Acta Derm Venereol. 2022;29: 102:adv00745. doi: 10.2340/actadv.v102.1000
   Web of Science ®Google Scholar
• Di Lernia V, Stingeni L, Boccaletti V, et al. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis. J Dermatol Treat. 2016;27(5):395–398.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Bonamonte D, Lasagni C, et al. Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis. Pediatr Dermatol. 2016;33(5):530–535.
   PubMed Web of Science ®Google Scholar
• Mahé E, Beauchet A, Hadj-Rabia S, et al. Biologic combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPed cohorts and a practice survey among French and Italian pediatric dermatologists. Dermatol Ther. 2022;35:e15828. doi: 10.1111/dth.15828
   PubMedGoogle Scholar
• Hanafi B, Beauchet A, Di Lernia V, et al. Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: an analysis of real-life data from the BiPe cohorts. Pediatr Dermatol. 2023;40(5):835–840.
   PubMedGoogle Scholar
• Xie X, Wang Y, Yao S, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33(4):2038–2050.
   PubMed Web of Science ®Google Scholar
• Bellinvia S, Fraser Cumings JR, Ardern-Jones MR, et al. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33:241–253. doi: 10.1007/s40259-019-00355-4
   PubMed Web of Science ®Google Scholar
• Car E, Vulto AG, Van Houdenhoven M, et al. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;21; 14:1151764. doi: 10.3389/fphar.2023.1151764
   Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74:280–287. doi: 10.1016/j.jaad.2015.09.056
   PubMed Web of Science ®Google Scholar
• Langley RG, Paller A, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64–70.
   PubMed Web of Science ®Google Scholar
• Gu Y, Brinkley E, Largent J, et al. A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting. Eur J Dermatol. 2023;33(1):25–33.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Guarneri C, Stingeni L, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J DermatolTreat. 2018;29(3):217–219.
   Google Scholar
• Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40–49.
   PubMed Web of Science ®Google Scholar
• Di Lernia V. Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation. Exp Op Biol Ther. 2017;17:1553–1556. doi: 10.1080/14712598.2017.1369950
   PubMed Web of Science ®Google Scholar
• Thaçi D, Papp K, Marcoux D, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181(6):1177–1189.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Bianchi L, Guerriero C, et al. Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation. Dermatol Ther. 2019;32(6):e13091.
   PubMed Web of Science ®Google Scholar
• Zitouni J, Beauchet A, Curmin R, et al. Effectiveness and safety of adalimumab, etanercept and ustekinumab for severe psoriasis in children under 12 years of age: a French-Italian daily practice cohort (BiPe jr). Paediatr Drugs. 2022;24(3):281–292.
   PubMed Web of Science ®Google Scholar
• Eickstaedt J, Paller AS, Lund E, et al. Paradoxical psoriasiform eruptions in children receiving tumor necrosis factor α inhibitors. JAMA Dermatol. 2023;159(6):637–642.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS jr study. Br J Dermatol. 2020;183:664–672. doi: 10.1111/bjd.19018
   PubMed Web of Science ®Google Scholar
• Schneeweiss MC, Savage TJ, Wyss R, et al. Risk of infection in children with psoriasis receiving treatment with ustekinumab, etanercept, or methotrexate before and after labeling expansion. JAMA Dermatol. 2023;159(3):289–298.
   PubMed Web of Science ®Google Scholar
• Mahé E, Geldhof A, Jazra M, et al. Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488). J Eur Acad Dermatol Venereol. 2022;36(8):e646–e648.
   PubMed Web of Science ®Google Scholar
• Phan C, Beauchet A, Burztejn AC, et al. Biological treatments for paediatric psoriasis: a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1984–1992. doi: 10.1111/jdv.15579
   PubMed Web of Science ®Google Scholar
• Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938–947.
   PubMed Web of Science ®Google Scholar
• Paller A, Seyger M, Magariños GA, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231–241.
   PubMed Web of Science ®Google Scholar
• Narbutt J, Niedźwiedź M, Lesiak A, et al. Secukinumab for the treatment of psoriasis in pediatrics: patient selection and acceptability. Patient Prefer Adherence. 2023;17:421–431. doi: 10.2147/PPA.S350753
   PubMed Web of Science ®Google Scholar
• Deng Z, Wang S, Wu C, et al. IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis. Front Pharmacol. 2023;14:1124628. doi: 10.3389/fphar.2023.1124628
   PubMed Web of Science ®Google Scholar
• Magnolo N, Kingo K, Laquer V, et al. Efficacy of secukinumab Across Subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs. 2022;24(4):377–387.
   PubMed Web of Science ®Google Scholar
• Krasowska D, Gambichler T, Cortés C, et al. Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: two-year results from a phase III double-blind, randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 Mar 27;37(8):1616–1625. doi: 10.1111/jdv.19063
   Web of Science ®Google Scholar
• Sticherling M, Nikkels AF, Hamza AM, et al. Secukinumab in pediatric patients with plaque psoriasis: Pooled safety analysis from two phase 3 randomized clinical trials. Am J Clin Dermatol. 2023;24(5):821–835.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Macca L, Peterle L, et al. Efficacy of systemic biologic drugs in pediatric psoriasis: evidence from five selected randomized clinical trials. Front Pharmacol. 2022;5; 13:847308. doi: 10.3389/fphar.2022.847308
   PubMed Web of Science ®Google Scholar
• Paller AS, Seyger MMB, Magariños GA, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022;158(5):533–541.
   PubMed Web of Science ®Google Scholar
• Hebert AA, Bobonich MA, Rodriguez Capriles C, et al. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis. Pediatr Dermatol. 2022;39(1):55–60.
   PubMed Web of Science ®Google Scholar
• Orsini D, Ibba L, Narcisi A, et al. Long-term management of pediatric psoriasis with ixekizumab: a case report. J DermatolTreat. 2023;34(1):2198622.
   Google Scholar
• Megna M, Fornaro L, De Lucia M, et al. A case of pediatric psoriasis successfully and rapidly treated with ixekizumab. Dermatol Ther. 2021;34(6):e15108.
   PubMed Web of Science ®Google Scholar
• Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82(2):389–397.
   PubMed Web of Science ®Google Scholar
• Mahé E, Tubach F, Jullien D, et al. Impact of childhood onset psoriasis on addictive behaviours, socioeconomic and Educational data in adulthood. Acta Derm Venereol. 2022;102:adv00733. doi: 10.2340/actadv.v102.2484
   PubMed Web of Science ®Google Scholar
• Mahé E, Beauchet A, Bodemer C, et al. Psoriasis and obesity in French children: a case-control, multicentre study. Br J Dermatol. 2015;172(6):1593–1600. doi: 10.1111/bjd.13507
   PubMed Web of Science ®Google Scholar
• Badaoui A, Tounian P, Mahé E. Psoriasis and metabolic and cardiovascular comorbidities in children: a systematic review. Arch Pediatr. 2019;26(2):86–94. doi: 10.1016/j.arcped.2018.12.005
   PubMed Web of Science ®Google Scholar
• Caroppo F, Belloni Fortina A. Psoriasis and comorbidities in children. Arch Pediatr. 2019;26(4):247. doi: 10.1016/j.arcped.2019.03.003
   PubMed Web of Science ®Google Scholar
• Caroppo F, Ventura L, Belloni Fortina A. High blood pressure in normal-weight children with psoriasis. Acta Derm Venereol. 2019;99(3):329–330. doi: 10.2340/00015555-3076
   PubMed Web of Science ®Google Scholar
• Caroppo F, Galderisi A, Ventura L, et al. Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis. Eur J Pediatr. 2021;180(6):1739–1745.
   PubMed Web of Science ®Google Scholar
• Torres T, Machado S, Mendonça D, et al. Cardiovascular comorbidities in childhood psoriasis. Eur J Dermatol. 2014;24(2):229–235. doi: 10.1684/ejd.2014.2291
   PubMed Web of Science ®Google Scholar
• Relvas M, Torres T. Pediatric psoriasis. Am J Clin Dermatol. 2017;18(6):797–811. doi: 10.1007/s40257-017-0294-9
   PubMed Web of Science ®Google Scholar
• Kampylafka E, Simon D, d’Oliveira I, et al. Disease interception with interleukin-17 inhibition in highrisk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21:178. 35. doi: 10.1186/s13075-019-1957-0
   Web of Science ®Google Scholar
• Savage L, Goodfield M, Horton L, et al. Regression of peripheral subclinical enthesopathy in therapy naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two week prospective, open-label feasibility study. Arthritis & Rheumat. 2019;71:626–631. doi: 10.1002/art.40778
   PubMed Web of Science ®Google Scholar
• Melin A, Sei JF, Corgibet F, et al. Therapeutic inertia in the management of moderate-to-severe plaque psoriasis in adolescents. Acta Derm Venereol. 2021;101(6):adv00475. doi: 10.2340/00015555-3813
   PubMedGoogle Scholar
• Mermin D, Boursault L, Milpied B, et al. DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis. J Eur Acad Dermatol Venereol. 2016;30(11):1961–1964.
   PubMed Web of Science ®Google Scholar
• Torres T, Henrique M, Oliveira H, et al. Management of psoriasis by family physicians: referral algorithm and shared management with Dermatology. Acta Med Port. 2021;34:682–689. doi: 10.20344/amp.13159
   PubMed Web of Science ®Google Scholar
• Diotallevi F, Simonetti O, Rizzetto G, et al. Biological treatments for pediatric psoriasis: state of the art and future perspectives. Int J Mol Sci. 2022;23(19):11128.
   PubMed Web of Science ®Google Scholar
• Messina F, Piaserico S. The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. J DermatolTreat. 2022;33(5):2443–2454. doi: 10.1080/09546634.2022.2062281
   Google Scholar